vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and Xeris Biopharma Holdings, Inc. (XERS). Click either name above to swap in a different company.
Xeris Biopharma Holdings, Inc. is the larger business by last-quarter revenue ($85.8M vs $75.5M, roughly 1.1× PUMA BIOTECHNOLOGY, INC.). On growth, Xeris Biopharma Holdings, Inc. posted the faster year-over-year revenue change (42.8% vs 27.7%). Over the past eight quarters, Xeris Biopharma Holdings, Inc.'s revenue compounded faster (45.3% CAGR vs 31.3%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
PBYI vs XERS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $85.8M |
| Net Profit | — | $11.1M |
| Gross Margin | 69.3% | — |
| Operating Margin | 22.7% | 19.5% |
| Net Margin | — | 12.9% |
| Revenue YoY | 27.7% | 42.8% |
| Net Profit YoY | — | 316.7% |
| EPS (diluted) | $0.26 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.5M | $85.8M | ||
| Q3 25 | $54.5M | $74.4M | ||
| Q2 25 | $52.4M | $71.5M | ||
| Q1 25 | $46.0M | $60.1M | ||
| Q4 24 | $59.1M | $60.1M | ||
| Q3 24 | $80.5M | $54.3M | ||
| Q2 24 | $47.1M | $48.1M | ||
| Q1 24 | $43.8M | $40.6M |
| Q4 25 | — | $11.1M | ||
| Q3 25 | $8.8M | $621.0K | ||
| Q2 25 | $5.9M | $-1.9M | ||
| Q1 25 | $3.0M | $-9.2M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | $20.3M | $-15.7M | ||
| Q2 24 | $-4.5M | $-15.0M | ||
| Q1 24 | $-4.8M | $-19.0M |
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
| Q4 25 | 22.7% | 19.5% | ||
| Q3 25 | 17.6% | 9.0% | ||
| Q2 25 | 12.7% | 6.3% | ||
| Q1 25 | 8.7% | -5.1% | ||
| Q4 24 | 22.6% | 2.8% | ||
| Q3 24 | 27.4% | -23.8% | ||
| Q2 24 | -4.6% | -17.0% | ||
| Q1 24 | -5.3% | -35.1% |
| Q4 25 | — | 12.9% | ||
| Q3 25 | 16.2% | 0.8% | ||
| Q2 25 | 11.2% | -2.7% | ||
| Q1 25 | 6.5% | -15.3% | ||
| Q4 24 | — | -8.5% | ||
| Q3 24 | 25.2% | -29.0% | ||
| Q2 24 | -9.6% | -31.2% | ||
| Q1 24 | -11.0% | -46.7% |
| Q4 25 | $0.26 | $0.07 | ||
| Q3 25 | $0.17 | $0.00 | ||
| Q2 25 | $0.12 | $-0.01 | ||
| Q1 25 | $0.06 | $-0.06 | ||
| Q4 24 | $0.40 | $-0.02 | ||
| Q3 24 | $0.41 | $-0.11 | ||
| Q2 24 | $-0.09 | $-0.10 | ||
| Q1 24 | $-0.10 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $111.0M |
| Total DebtLower is stronger | $22.7M | $220.3M |
| Stockholders' EquityBook value | $130.3M | $13.7M |
| Total Assets | $216.3M | $383.5M |
| Debt / EquityLower = less leverage | 0.17× | 16.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $97.5M | $111.0M | ||
| Q3 25 | $94.4M | $91.6M | ||
| Q2 25 | $96.0M | $59.3M | ||
| Q1 25 | $93.2M | $58.4M | ||
| Q4 24 | $101.0M | $71.6M | ||
| Q3 24 | $96.7M | $69.4M | ||
| Q2 24 | $96.8M | $77.6M | ||
| Q1 24 | $107.2M | $87.4M |
| Q4 25 | $22.7M | $220.3M | ||
| Q3 25 | $34.0M | $219.5M | ||
| Q2 25 | $45.3M | $218.6M | ||
| Q1 25 | $56.7M | $229.8M | ||
| Q4 24 | $68.0M | $232.1M | ||
| Q3 24 | $79.3M | $216.2M | ||
| Q2 24 | $90.7M | $230.5M | ||
| Q1 24 | $102.0M | $229.7M |
| Q4 25 | $130.3M | $13.7M | ||
| Q3 25 | $115.3M | $-861.0K | ||
| Q2 25 | $104.7M | $-19.3M | ||
| Q1 25 | $97.1M | $-35.1M | ||
| Q4 24 | $92.1M | $-29.6M | ||
| Q3 24 | $71.1M | $-28.3M | ||
| Q2 24 | $48.5M | $-19.3M | ||
| Q1 24 | $51.0M | $-9.2M |
| Q4 25 | $216.3M | $383.5M | ||
| Q3 25 | $202.9M | $370.2M | ||
| Q2 25 | $194.9M | $334.7M | ||
| Q1 25 | $196.2M | $315.5M | ||
| Q4 24 | $213.3M | $323.1M | ||
| Q3 24 | $220.7M | $321.1M | ||
| Q2 24 | $205.0M | $331.7M | ||
| Q1 24 | $214.1M | $336.6M |
| Q4 25 | 0.17× | 16.10× | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | $20.0M |
| Free Cash FlowOCF − Capex | $14.4M | — |
| FCF MarginFCF / Revenue | 19.1% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $20.0M | ||
| Q3 25 | $9.7M | $18.4M | ||
| Q2 25 | $14.1M | $182.0K | ||
| Q1 25 | $3.6M | $-10.0M | ||
| Q4 24 | $15.6M | $2.0M | ||
| Q3 24 | $11.0M | $-8.3M | ||
| Q2 24 | $1.0M | $-10.3M | ||
| Q1 24 | $11.2M | $-20.3M |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | 1.81× | ||
| Q3 25 | 1.10× | 29.68× | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PBYI
Segment breakdown not available.
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
